We are live on
!
Find out more
Atara Biotherapeutics
ATRA
ATRA
148 hedge funds and large institutions have $1.7B invested in Atara Biotherapeutics in 2020 Q4 according to their latest regulatory filings, with 28 funds opening new positions, 58 increasing their positions, 44 reducing their positions, and 20 closing their positions.
New
Increased
Maintained
Reduced
Closed
60% more capital invested
Capital invested by funds: $1.06B → $1.7B (+$635M)
40% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 20
32% more repeat investments, than reductions
Existing positions increased: 58 | Existing positions reduced: 44
6% more funds holding
Funds holding: 140 → 148 (+8)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0.25% less ownership
Funds ownership: 4.44% → 4.18% (-0.25%)
3% less call options, than puts
Call options by funds: $1.76M | Put options by funds: $1.82M
Holders
148
Holders Change
+8
Holders Change %
+5.71%
% of All Funds
2.62%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
28
Increased
58
Reduced
44
Closed
20
Calls
$1.76M
Puts
$1.82M
Net Calls
-$59K
Net Calls Change
-$1.04M
Top Buyers
| 1 |
Morgan Stanley
New York
|
+$42.7M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$20.8M |
| 3 |
Citigroup
New York
|
+$20.1M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$15.5M |
| 5 |
JP Morgan Chase
New York
|
+$11.6M |
